Berlin - Delayed Quote • EUR Aptorum Group Ltd (A1V0.BE) Follow 2.9310 0.0000 (0.00%) At close: July 15 at 10:00:00 PM GMT+2 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024 NEW YORK, December 20, 2024--Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update NEW YORK & LONDON, April 30, 2024--Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group" or "We"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business NEW YORK & LONDON, March 06, 2024--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company ("Aptorum"), and privately-held YOOV Group Holding Ltd. ("YOOV") jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"). The Merger Agreement was approved by Aptorum’s and YOOV’s boards of directors (each board of directors, the "Board"), respectively. If the Merger Agreement is approved by Apto